A study published in the Journal of Clinical Oncology found that rucaparib can successfully treat patients with metastatic castration-resistant prostate cancer who have mutated BRCA/BRCA2 genes.
PFS and OS were significantly improved with subcutaneous daratumumab vs active monitoring in patients with smoldering multiple myeloma.
Daratumumab plus VRd showed a deepened MRD and PFS rate for patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma.
Acalabrutinib-based treatment also improves overall survival vs standard chemoimmunotherapy in the phase 3 AMPLIFY trial.
Almost a 100% complete response rate was noted with Zilovertamab Vedotin/R-CHP for patients with DLBCL.
Panelists discuss how the evolving treatment landscape for HER2-overexpressing NSCLC, particularly with the introduction of trastuzumab deruxtecan, influences therapeutic strategies and decision-making based on recent…
Data from the phase 3 ASC4FIRST trial support asciminib as a standard of care in newly diagnosed chronic myeloid leukemia in chronic phase.
For patients with relapsed or refractory KMT2Ar acute leukemia, revumenib showed promising outcomes of overall response rate and duration of response.
For patients with relapsed/refractory diffuse large b-cell lymphoma, meaningful efficacy outcomes were shown with FS118.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Bicistronic CD19/CD22 CAR T-cell therapy had improved safety, durability, and high remission rates in pediatric patients with R/R B-ALL.
